Balance Sheet

Current Liabilities	72.8m
Accounts Payable	8.1m
Accrued Liabilities	35.6m
Other Current Liabilities	29m
Non-Current Liabilities	170.3m
Other Non-Current Liabilities	170.3m

Currency: USD

	Dec-2015	Dec-2016	Dec-2017	Dec-2018	Dec-2019	Dec-2020	Dec-2021	Dec-2022	Dec-2023
Assets
Cash & Cash Equivalents	194	159	84	68	50	57	150	108	144
Cash Equivalents	194	159	84	68	50	57	150	108	144
Short-Term Investments	55	23	124	137	39	311	220	97	3
Total Receivables	1	2	0	18	21	21	34	38	47
Accounts Receivables	1	2	0	0	0	0	1	7	1
Other Receivables	0	0	0	18	21	21	33	31	46
Other Current Assets	13	16	22	8	10	9	12	13	14
Total Current Assets	263	199	230	231	121	398	416	255	208
PP&E Net	13	28	41	36	52	47	51	72	72
PP&E Gross	13	28	41	36	52	47	51	72	72
Accumulated Depreciation	2	5	10	16	24	31	36	39	46
Intangible Assets	0	1	1	2	2	2	1	0	0
Other Long-Term Assets	9	7	9	8	7	5	2	2	3
Total Assets	286 N/A	235 -18%	281 +20%	277 -2%	182 -34%	451 +149%	470 +4%	329 -30%	283 -14%
Liabilities
Accounts Payable	8	11	8	4	6	6	8	5	8
Accrued Liabilities	7	16	27	20	26	30	32	32	36
Short-Term Debt	0	0	0	0	0	0	0	0	0
Other Current Liabilities	13	13	39	0	2	3	23	28	29
Total Current Liabilities	28	40	74	24	34	39	63	65	73
Long-Term Debt	0	0	0	0	0	0	0	0	0
Other Liabilities	23	28	4	5	24	71	201	183	170
Total Liabilities	51 N/A	68 +35%	78 +14%	30 -62%	58 +94%	110 +90%	264 +140%	247 -6%	243 -2%
Equity
Common Stock	1	1	1	1	1	1	1	1	2
Retained Earnings	90	162	232	319	456	586	744	909	1 023
Additional Paid In Capital	332	341	455	574	586	936	960	991	1 065
Unrealized Security Profit/Loss	0	0	0	0	0	0	0	1	0
Other Equity	8	14	22	10	7	10	11	0	4
Total Equity	235 N/A	166 -29%	203 +22%	247 +22%	124 -50%	341 +176%	206 -40%	82 -60%	40 -52%
Total Liabilities & Equity	286 N/A	235 -18%	281 +20%	277 -2%	182 -34%	451 +149%	470 +4%	329 -30%	283 -14%
Shares Outstanding
Common Shares Outstanding	425	425	562	628	631	929	938	987	1 363

Adaptimmune Therapeutics PLC
NASDAQ:ADAP